12 results about "ROR1" patented technology

This invention discloses antibodies against ROR1 or their antigen-binding fragments, kits, and their applications, relating to the fields of biotechnology and medical technology. This invention screened and obtained 10 antibodies that have high affinity for the ROR1 protein and can specifically bind to it. This allows for the development of ROR1 detection kits, tumor diagnostic and prognostic kits, as well as pharmaceutical compositions, antibody-drug conjugates, or other therapeutic methods using the aforementioned antibodies or their antigen-binding fragments. Experimental verification shows that the antibodies provided by this invention have a high killing rate against tumor cells. All of the above antibodies exhibit concentration-dependent cytotoxicity; the higher the antibody concentration, the better the anti-tumor activity. Therefore, the antibodies or their antigen-binding fragments provided by this invention show promising potential for the preparation of tumor therapeutic drugs.

The present application relates to an isolated antigen binding protein capable of binding to ROR1 (Receptor Tyrosine Kinase Orphan Receptor 1), said isolated antigen protein comprising CDR1, CDR2 and CDR3. The present application also provides a method for preparing said isolated antigen binding protein and uses thereof.

The invention relates to an antibody aiming at ROR1 and application thereof, in particular to an antibody specifically bound with ROR1 or an antigen binding fragment thereof, a nucleic acid for coding the antibody, a vector comprising the nucleic acid and a host cell comprising the nucleic acid or the vector. Compositions, kits and conjugates comprising the antibodies, as well as medical uses of the antibodies.

Provided herein are bispecific and multispecific antibodies that target tumor antigens and 4-1BB, the Fc region of which has a retained or enhanced effector function; in particular, the multispecific antibodies have binding specificity for human ROR1 protein and human 4-1BB protein. Also provided herein are methods of treating cancer using the antibodies or fragments thereof.

Provided are bispecific antibodies targeting ROR1 and CD3 and uses thereof, the bispecific antibodies comprising a first antigen-binding moiety and a second antigen-binding moiety wherein the first antigen-binding moiety is an antibody or antigen-binding fragment thereof that specifically binds to ROR1 and the second antigen-binding moiety is an antibody or antigen-binding fragment thereof that specifically binds to CD3.

Single-domain antibodies that bind receptor tyrosine kinase (ROR1) are described. The single-domain antibodies can be used for multiple purposes including in research, imaging, diagnosis, and treatment of ROR1-related conditions. The disclosed single-domain antibodies can be used as anti-cancer therapeutics such as antibody-drug conjugates, multi-domain binding molecules, or recombinant receptors or can be used as cancer imaging / diagnostic agents.

This invention discloses a peroxisome-targeting chimeric compound, PexTAC, and its applications, belonging to the field of target protein degradation technology. The invention provides a peroxisome-targeting chimeric compound, PexTAC, with the general structural formula A-L-B, where A is the peroxisome-targeting module, L is the linker, and B is the target protein recognition module. PexTAC recruits target proteins to the peroxisome membrane and utilizes the endogenous E3 ubiquitin ligase SYVN1 for specific degradation via the proteasome pathway. This platform can not only target ROR1 to inhibit tumor growth but also induce ferroptosis through the bispecific PexTAC synergistic degradation of HSPA5 and GPX4. This invention overcomes the dependence of traditional PROTAC technology on limited E3 ligases, providing a novel modular degradation strategy for targeting "undruggable" proteins and organelle-related proteins.

The present disclosure provides anti-tyrosine protein kinase membrane receptor 1 antibody-drug conjugate structures. The antibody-drug conjugate structure comprises branched linkers, wherein each branched linker links two or more payloads to an antibody. In addition, the present disclosure also encompasses compounds and methods for producing such conjugates. In addition, the present disclosure also encompasses methods of using the conjugates.

The present invention provides antibodies targeting ROR1, as well as multispecific antibodies, chimeric antigen receptors, antibody conjugates, pharmaceutical compositions and kits comprising the same, and their use in the diagnosis / treatment / prevention of diseases associated with ROR1 expression.

The present application relates to an isolated antigen binding protein capable of binding to ROR1 (Receptor Tyrosine Kinase Orphan Receptor 1), said isolated antigen protein comprising CDR1, CDR2 and CDR3. The present application also provides a method for preparing said isolated antigen binding protein and uses thereof.

The application discloses an antibody against ROR1 and application thereof, and relates to the technical fields of biotechnology and medicine. Ten antibodies are screened and obtained, the antibodies have high affinity to ROR1 protein, and can specifically combine with the ROR1 protein, so that an ROR1 detection kit containing the antibodies, a tumor diagnosis kit, a prognosis kit, a pharmaceutical composition, an antibody-drug conjugate and other treatment methods using the antibodies can be developed. It is verified through experiments that the antibody has high killing rate on tumor cells, and the higher the antibody concentration is, the better the anti-tumor activity is. Therefore, the antibody or the antigen binding fragment thereof has good prospects for preparing an anti-tumor drug.